Feed aggregator

ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird

Biospace news - Mon, 08/05/2024 - 02:00
ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird 5/8/2024

Generative AI Finds Its Footing in Drug Development

Biospace news - Mon, 08/05/2024 - 02:00
Generative AI Finds Its Footing in Drug Development 5/8/2024

BMS, J&J Losses Not the End of IRA Legal Battle

Biospace news - Mon, 08/05/2024 - 02:00
BMS, J&J Losses Not the End of IRA Legal Battle 5/8/2024

Merck Snaps Up Small Startup in $208M Deal, Seeks to Improve Safety of ADCs

Biospace news - Sun, 08/04/2024 - 02:00
Merck Snaps Up Small Startup in $208M Deal, Seeks to Improve Safety of ADCs 4/8/2024

BMS Sees Early ROI for $14B Karuna Buy with Phase III Schizophrenia Win

Biospace news - Sun, 08/04/2024 - 02:00
BMS Sees Early ROI for $14B Karuna Buy with Phase III Schizophrenia Win 4/8/2024

ACC24 Roundup: Novo, Ionis Tout Cardio Victories and Boehringer, Lilly Disappoint

Biospace news - Sun, 08/04/2024 - 02:00
ACC24 Roundup: Novo, Ionis Tout Cardio Victories and Boehringer, Lilly Disappoint 4/8/2024

5 Successful Phase III Oncology Trials in Q1

Biospace news - Sun, 08/04/2024 - 02:00
5 Successful Phase III Oncology Trials in Q1 4/8/2024

The Next Wave of ADCs Could Treat Evasive Solid Tumors

Biospace news - Sun, 08/04/2024 - 02:00
The Next Wave of ADCs Could Treat Evasive Solid Tumors 4/8/2024

AstraZeneca, Daiichi Sankyo Win First Tumor-Agnostic HER2 FDA Approval for Enhertu

Biospace news - Sun, 08/04/2024 - 02:00
AstraZeneca, Daiichi Sankyo Win First Tumor-Agnostic HER2 FDA Approval for Enhertu 4/8/2024

FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease

Biospace news - Sun, 08/04/2024 - 02:00
FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease 4/8/2024

Opinion: The Next Generation of ADCs Will Improve Cancer Treatment

Biospace news - Sun, 08/04/2024 - 02:00
Opinion: The Next Generation of ADCs Will Improve Cancer Treatment 4/8/2024

RSV Vaccine Makers Hit Hard by New CDC Guidelines

Biospace news - Fri, 08/02/2024 - 02:00
GSK, Moderna and Pfizer are all looking at potential respiratory syncytial virus vaccine sales slumps thanks to recently updated CDC guidelines regarding the use of RSV shots in seniors.